Search over 3,000 reports

    Actinic Keratosis- Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025

    Actinic Keratosis- Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025
    Date: Dec, 2017
    Type: Pharmaceutical Industry Report
    Pages: 132
    Geography: Global
    Delivery Timeline: 5 days
    SKU: DISR0011
    DelveInsight's "Actinic Keratosis - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025"report provides the comprehensive insights on the competitive landscape and market of Actinic Keratosis (AK).
    The Report covers an overview of the disease and global market trends of the Actinic Keratosis for the seven major markets i.e., United States, Europe (France, Germany, Italy, Spain, and UK) and Japan. The Report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Actinic Keratosis from 2017 to 2025 segmented by seven major markets. The market size covered in our report is based only upon the topical therapies approved for Actinic Keratosis which represents around 5% of the total market size of Actinic Keratosis.
    In addition, the report also includes global forecast of epidemiology of Actinic Keratosis till 2025.The Report also covers market drivers, market barriers and unmet medical need.
    The competitive landscape of the report covers both pipeline and marketed portfolio of the indication. Actinic Keratosis pipeline provides information on the therapeutic drugs in development and comparative analysis at various stages covering clinical and pre-clinical & discovery stages, therapeutics assessment by Monotherapy/ Combination products and Molecule Type drug analysis. It also provides in-depth analysis on the Phase III profile covering clinical trial studies, recent developments and SWOT Analysis.
    United States accounts for the highest number of prevalent cases of Actinic Keratosis as compared to EU5 and Japan. As per DelveInsight forecasts, 76,603,272 cases of Actinic Keratosis were prevalent in the United States in the year 2015. This number is expected to grow at a CAGR of XX% from 2015 to 2025.
    The Topical Therapy of Actinic Keratosis considered in our report include Ingenol mebutate, Diclofenac 3%, Imiquimod 5%, 5-Fluorouracil 5%, Imiquimod 3.75% and Fluorouracil/Salicylic acid combination. Patient adherence is generally low, around 50%-55% when it comes to topical treatment. High percentage of non-adherence to the regimen has been observed amongst the patients opting for topical therapy owing to the long treatment duration. The procedural therapy still remains the standard of care.
    United States contributes the major share of the Actinic keratosis(AK) market as compared to EU5 countries and Japan. According to DelveInsight estimation, the market size of Actinic Keratosis (topical therapies only) in the United States, was estimated to be USD 102.62 Millions in 2015 and is expected to grow at a CAGR of XX% from 2015 to 2025.
    Scope
    Overview of the Global pipeline scenario for Actinic Keratosis, products and associated companies information
    Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities
    Organize sales and marketing efforts by identifying the best opportunities for Actinic Keratosis in US, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
    To understand the future market competition in the global Actinic Keratosis market and Insightful review of the key market drivers and barriers.
    The report will help in developing business strategies by understanding the trends shaping and driving the global Actinic Keratosis market.
    Key topics covered include strategic competitor assessment, barriers and drivers in the market along with SWOT analysis
    The Report also covers the detailed global historical and forecasted Actinic Keratosis market covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025.
    Report Introduction
    Actinic Keratosis Market Overview at a Glance
    Global Market Size of Actinic Keratosis in 2016
    Global Market Size of Actinic Keratosis in 2025
    Actinic Keratosis: Overview
    • Causes
    • Signs and symptoms
    • Risk Factors
    • Pathophysiology/ Mechanisms of action
    • Diagnosis
    Epidemiology and Patient Population
    Assumptions and Caveats
    United States
    • Prevalent Population of Actinic Keratosis in United States (2015-2025)
    Europe
    • Germany
    o Prevalent Population of Actinic Keratosis in Germany (2015-2025)
    • Italy
    o Prevalent Population of Actinic Keratosis in Italy (2015-2025)
    • Spain
    o Prevalent Population of Actinic Keratosis in Spain (2015-2025)
    • France
    o Prevalent Population of Actinic Keratosis in France (2015-2025)
    • United Kingdom
    o Prevalent Population of Actinic Keratosis in United Kingdom (2015-2025)
    Japan
    • Prevalent Population of Actinic Keratosis in Japan (2015-2025)
    Treatment Algorithm
    • Lesion-Directed Therapies:
    • Field-Directed Therapies
    • Photodynamic therapy
    Competitive Marketed Drug Landscape
    Ameluz (aminolevulinic acid hydrochloride): Biofrontera Pharma
    • Drug Description
    • Mechanism of Action
    • Regulatory Milestones
    • Advantages & Disadvantages
    • Safety and Efficacy
    • Product Profile
    Marketed Drug List Continued…
    Competitive Pipeline Landscape
    Clinical Stage Products
    • Comparative Analysis
    Pre-Clinical Stage Products
    • Comparative Analysis
    Therapeutic Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Route of Administration
    • Assessment by Stage and Route of Administration
    • Assessment by Molecule Type
    • Assessment by Stage and Molecule Type
    • Assessment by Domain
    • Assessment by Stage and Domain
    Actinic Keratosis: Region-Specific Market Analysis
    • Region-Specific Market Distribution and Comparison
    • Overview on Actinic Keratosis Market (2016)
    • Overview on Actinic Keratosis Market (2025)
    Global Market Outlook - Actinic Keratosis
    United States
    • Market Outlook
    • Market Size
    Europe
    Market Outlook
    Germany
    Market Size
    France
    Market Size
    Italy
    Market Size
    Spain
    Market Size
    United Kingdom
    Market Size
    Japan
    Market Outlook
    Market Size
    Market Drivers
    Market Restraints
    Unmet Needs
    Appendix
    Report Methodology
    Consulting Services
    Disclaimer
    About DelveInsight
    Table 1: Prevalent and Treatable Population of Actinic Keratosis in United States (2015-2025)
    Table 2: Prevalent and Treatable Population of Actinic Keratosis in Germany (2015-2025)
    Table 3: Prevalent and Treatable Population of Actinic Keratosis in Italy (2015-2025)
    Table 4: Prevalent and Treatable Population of Actinic Keratosis in Spain (2015-2025)
    Table 5: Prevalent and Treatable Population of Actinic Keratosis in France (2015-2025)
    Table 6: Prevalent and Treatable Population of Actinic Keratosis in United Kingdom (2015-2025)
    Table 7: Prevalent and Treatable Population of Actinic Keratosis in Japan (2015-2025)
    Table 8: Ingenol Disoxate, Clinical Trials by Zone, 2017
    Table 9:Clinical Trials by Recruitment status, 2017
    Table 10: Number of Products under development by Companies, 2017
    Table 11: Clinical Stage Products, 2017
    Table 12: Pre-Clinical Stage Products, 2017
    Table 13: Assessment by Monotherapy Products, 2017
    Table 14: Assessment by Combination Products, 2017
    Table 15: Assessment by Route Of Administration, 2017
    Table 16: Assessment by Stage and Route Of Administration, 2017
    Table 17: Assessment by Molecule Type, 2017
    Table 18: Assessment by Stage and Molecule Type, 2017
    Table 19: Assessment by Stage of development and Domain, 2017
    Table 20: Assessment by Stage of development and Domain, 2017
    Table 21: Total Market size of Actinic Keratosis in USD Million (2015-2025)
    Table 22: United States Market Size of Actinic Keratosis in USD, Million (2015-2025)
    Table 23: Germany Market Size of Actinic Keratosis in USD, Million (2015-2025)
    Table 24: Italy Market Size of Actinic Keratosis in USD, Million (2015-2025)
    Table 25: Spain Market Size of Actinic Keratosis in USD, Million (2015-2025)
    Table 26: France Market Size of Actinic Keratosis in USD, Million (2015-2025)
    Table 27: United Kingdom Market Size of Actinic Keratosis in USD, Million (2015-2025)
    Table 28:Japan Market Size of Actinic Keratosis in USD, Million (2015-2025)
    Figure 1: Prevalent and Treatable Population of Actinic Keratosis in United States (2015-2025)
    Figure 2: Prevalent and Treatable Population of Actinic Keratosis in Germany (2015-2025)
    Figure 3: Prevalent and Treatable Population of Actinic Keratosis in Italy (2015-2025)
    Figure 4: Prevalent and Treatable Population of Actinic Keratosis in Spain (2015-2025)
    Figure 5: Prevalent and Treatable Population of Actinic Keratosis in France (2015-2025)
    Figure 6: Prevalent and Treatable Population of Actinic Keratosis in United Kingdom (2015-2025)
    Figure 7: Prevalent and Treatable Population of Actinic Keratosis in Japan (2015-2025)
    Figure 8: IngenolDisoxate, Clinical Trials by Zone, 2017
    Figure 9:Clinical Trials by Recruitment status, 2017
    Figure 10: Number of Products under development by Companies, 2017
    Figure 11: Clinical Stage Products, 2017
    Figure 12: Pre-Clinical Stage Products, 2017
    Figure 13: Assessment by Monotherapy Products, 2017
    Figure 14: Assessment by Combination Products, 2017
    Figure 15: Assessment by Route Of Administration, 2017
    Figure 16: Assessment by Stage and Route Of Administration, 2017
    Figure 17: Assessment by Molecule Type, 2017
    Figure 18: Assessment by Stage and Molecule Type, 2017
    Figure 19: Assessment by Stage of development and Domain, 2017
    Figure 20: Assessment by Stage of development and Domain, 2017
    Figure 21: Total Market size of Actinic Keratosis in USD Million (2015-2025)
    Figure 22: United States Market Size of Actinic Keratosis in USD, Million (2015-2025)
    Figure 23: Germany Market Size of Actinic Keratosis in USD, Million (2015-2025)
    Figure 24: Italy Market Size of Actinic Keratosis in USD, Million (2015-2025)
    Figure 25: Spain Market Size of Actinic Keratosis in USD, Million (2015-2025)
    Figure 26: France Market Size of Actinic Keratosis in USD, Million (2015-2025)
    Figure 27: United Kingdom Market Size of Actinic Keratosis in USD, Million (2015-2025)
    Figure 28:Japan Market Size of Actinic Keratosis in USD, Million (2015-2025)
    Valeant Pharmaceuticals

    Sandoz Pharmaceuticals

    Leo Pharma

    Gage Development Company

    • Single User License
      (20% Off)
      $6,950.00
    • Site License
      (30% Off)
      $13,900.00
    • Global License
      (40% Off)
      $20,850.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap